A PHASE 1 STUDY OF MILADEMETAN IN COMBINATION WITH QUIZARTINIB IN SUBJECTS WITH FLT3-ITD MUTANT ACUTE MYELOID LEUKEMIA THAT ARE RELAPSED/REFRACTORY OR NEWLY DIAGNOSED AND UNFIT FOR INTENSIVE CHEMOTHERAPY
Brief description of study
To determine the safety and tolerability of the drug combination, identification of the optimum dosing schedule, MTD, and the recommended dose for expansion cohort (RDE). Part 2 (Dose Expansion): To confirm safety and tolerability of the combination therapy at RDE and identify the recommended Phase 2 dose.
Clinical Study Identifier: s19-00590
ClinicalTrials.gov Identifier: NCT03552029
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
